High Risk of Major Bleeding Observed in Danish A-fib Population on Triple, Dual Antithrombotic Therapy
Patients with atrial fibrillation who are prescribed triple therapy with either a vitamin K antagonist (VKA) or direct oral anticoagulant (DOAC) are at a much higher risk of major bleeding compared with those on VKA monotherapy, according to a nationwide cohort study. “The high rates of major bleeding found among patients receiving triple therapy raises the question whether concomitant use of three antithrombotic drugs is advisable,” lead author Nienke van Rein, PhD, and colleagues write in their paper published online ahead of print in Circulation.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063